TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer | MicrobiomeTrials← Back to trialsNCT03964532
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2019-04-19Est. Completion: 2027-04
Enrollment target: 24 participants Locations- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in
Hormone Receptor-Positive Breast CancerHER2 Low Breast CarcinomaEarly-Stage Breast Cancer
This is a single-center, open-label, randomized phase II clinical trial designed to evaluate the efficacy and safety of …
Guangzhou, ChinaEst. completion Sep 15, 2028
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8
Estrogen Receptor-Positive Breast Carcinoma
HER2-Negative Breast Carcinoma
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone thera…
Jonesboro, United StatesEst. completion Jul 31, 2029